Arcutis Biotherapeutics Q1 2024 Earnings Report $14.62 +0.06 (+0.41%) As of 01/3/2025 05:38 PM Eastern Earnings HistoryForecast Arcutis Biotherapeutics EPS ResultsActual EPS-$0.32Consensus EPS -$0.60Beat/MissBeat by +$0.28One Year Ago EPS-$1.31Arcutis Biotherapeutics Revenue ResultsActual Revenue$49.57 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AArcutis Biotherapeutics Announcement DetailsQuarterQ1 2024Date5/14/2024TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptSlide DeckPress ReleaseSEC FilingARQT Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by Arcutis Biotherapeutics Earnings HeadlinesPatrick Burnett Sells 1,691 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) StockJanuary 2 at 4:45 AM | americanbankingnews.comArcutis Biotherapeutics (NASDAQ:ARQT) Now Covered by Analysts at HC WainwrightDecember 31, 2024 | americanbankingnews.com3 golden rules for dividends If you have any interest in building a great dividend portfolio, you will want to watch legend, Jack Carter’s briefing asap: The 3 Golden Rules for a Powerhouse Dividend Portfolio During this class, Jack walks you through all three of his “golden rules” and how they work. He even shares specific tickers that meet his criteria which you could consider adding to your portfolio today! And he explains each of his golden rules in detail.January 5, 2025 | Jack Carter Trading (Ad)Arcutis Biotherapeutics initiated with a Buy at H.C. WainwrightDecember 31, 2024 | markets.businessinsider.comAmerican Air upgraded, Nordstrom downgraded: Wall Street's top analyst callsDecember 30, 2024 | finance.yahoo.comHC Wainwright & Co. Initiates Coverage of Arcutis Biotherapeutics (ARQT) with Buy RecommendationDecember 30, 2024 | msn.comSee More Arcutis Biotherapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arcutis Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arcutis Biotherapeutics and other key companies, straight to your email. Email Address About Arcutis BiotherapeuticsArcutis Biotherapeutics (NASDAQ:ARQT), a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.View Arcutis Biotherapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles S&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Upcoming Earnings Schlumberger (1/17/2025)Procter & Gamble (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
